New shot could tame hay fever misery
NCT ID NCT07199257
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an injection called GR1802, given alongside usual allergy treatments, to see if it can better control symptoms like sneezing, runny nose, and itchy eyes in people with seasonal allergic rhinitis (hay fever). About 144 adults who have had poor symptom control with standard therapies will participate. The goal is to reduce symptom severity and improve quality of life during allergy season.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 144 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2025
An estimate. Start dates often move.
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
12 to 18 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Main Inclusion Criteria: 1. Voluntarily sign the informed consent form. 2. Seasonal allergic rhinitis has been prevalent for at least 2 years.Positive for allergens associated with seasonal allergic rhinitis. 3. Poor control of seasonal allergic rhinitis with nasal glucocorticoids or other therapeutic agents during the same pollen season in the past. 4. Weight≥30kg. 5. Symptom severity scores for the season met the enrollment criteria. Main Exclusion Criteria: 1. Other nasal comorbidities or co-morbidities/states that may be present at the time of screening that affect efficacy determination. 2. Subjects whose allergen exposures in their home or work environments may be expected to change significantly during the trial period. 3. Subjects with poorly controlled recent asthma conditions. 4. Presence of current or past history of infection of special concern, e.g., active tuberculosis, helminthic infections, severe herpes virus infections, etc. 5. Previous use of anti-interleukin 4 receptor alpha subunit (IL4Rα) monoclonal antibody. 6. Have a serious underlying medical condition that, in the opinion of the investigator, may pose a risk to subject safety by participation in a clinical trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Allergic rhinitis, seasonal are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Zhongnan Hospital of Wuhan university
Wuhan, Hubei, 430000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.